Showing results (81-90 of 192) with videos related to
Sort By:
Pageof 20
The Oncologist|April 7, 2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Aaron R Hansen, Ian F Tannock, Arnoud Templeton, et al.Journal of Cancer Research and Clinical Oncology|October 12, 2022
Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancerWendy W Y Choi, Catherine Sánchez, Jiao Jiao Li, et al.Epigenomics|September 2, 2020
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatmentMadonna R Peter, Misha Bilenky, Ruth Isserlin, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.British Journal of Cancer|May 21, 2019
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trialGrainne M O'Kane, Shereen Ezzat, Anthony M Joshua, et al.Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.Cancer Research Communications|March 6, 2026
A phase I study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): dose escalation resultsBarak Talmor, Stefano Marastoni, Brandon Lau, et al.Pageof 20